Adult granulosa cell tumor of the ovary · line 1 · Carboplatin + Paclitaxel (adult granulosa cell tumor, advanced/recurrent)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-CARBOPLATIN-PACLITAXEL-GCT |
| ID | IND-GRANULOSA-CELL-1L-CARBOPLATIN-PACLITAXEL |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-04 | pending_clinical_signoff |
| Diseases | DIS-GRANULOSA-CELL |
| Sources | SRC-ESMO-OVARIAN-2024 SRC-NCCN-OVARIAN-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. No FDA-approved targeted therapy for AGCT; platinum-taxane is extrapolated standard. Both carboplatin and paclitaxel are NSZU-reimbursed in Ukraine. FOXL2 mutation testing confirms diagnosis but does not select therapy. CDK4/6 inhibitor trials ongoing.
Used By
Algorithms
ALGO-GRANULOSA-CELL-1L- ALGO-GRANULOSA-CELL-1L